# Nkarta, Inc.: overview NKTX · Nasdaq · CIK 1787400 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/nktx.md) · [Financials](/companies/nktx/financials.md) · [Filings](/companies/nktx/filings.md) · [Insiders](/companies/nktx/insiders.md) Latest reported revenue: [$0](/filings/0001564590-21-015517.md) for period not labelled, three months to 2019-12-31, from the 10-K filed Mar 25, 2021 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001564590-21-015517). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.39)](/filings/0001193125-25-274304.md) | not reported | [(0.43)](/filings/0001787400-26-000013.md) | [(0.31)](/filings/0001787400-26-000017.md) | [(0.29)](/filings/0001193125-25-274304.md) | not reported | [(0.37)](/filings/0001787400-26-000013.md) | [(0.54)](/filings/0001787400-26-000017.md) | | Free cash flow | $m | [(25.3) d](/filings/0001193125-25-274304.md) | [(25.9) d](/filings/0001787400-26-000006.md) | [(30.1)](/filings/0001787400-26-000013.md) | [(18.9) d](/filings/0001787400-26-000017.md) | [(18.7) d](/filings/0001193125-25-274304.md) | [(22.2) d](/filings/0001787400-26-000006.md) | [(28.6)](/filings/0001787400-26-000013.md) | [(24.4) d](/filings/0001787400-26-000017.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | [0.0](/filings/0000950170-25-045262.md) | [0.0](/filings/0001787400-26-000006.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.62)](/filings/0000950170-23-008523.md) | [(2.61)](/filings/0000950170-24-034735.md) | [(2.40)](/filings/0000950170-25-045262.md) | [(1.60)](/filings/0001787400-26-000006.md) | [(1.41)](/filings/0001787400-26-000006.md) | | Free cash flow | $m | [(73.0)](/filings/0000950170-23-008523.md) | [(104)](/filings/0000950170-24-034735.md) | [(114)](/filings/0000950170-25-045262.md) | [(104)](/filings/0001787400-26-000006.md) | [(89.9)](/filings/0001787400-26-000006.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nktx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $30.6m | 10,805,129 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $17.8m | 6,300,212 | | Added +1,791,739 | | [NEA Management Company, LLC](/funds/1512848.md) | 2026-06-30 | $10.1m | 3,568,781 | | Unchanged | | [SAMSARA BIOCAPITAL, LLC](/funds/1744967.md) | 2026-06-30 | $9.9m | 3,507,666 | | Unchanged | | [SR One Capital Management, LP](/funds/1910264.md) | 2026-06-30 | $9.4m | 3,333,333 | | Unchanged | | [GSK plc](/funds/1131399.md) | 2026-06-30 | $8.9m | 3,150,732 | | Unchanged | | [Monaco Asset Management SAM](/funds/1803593.md) | 2026-06-30 | $6.7m | 2,373,400 | | Reduced −148,532 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $6.3m | 2,226,415 | | Added +214,994 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $6.2m | 2,174,745 | | Added +390,751 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $5.3m | 1,873,293 | | Reduced −174,083 | ## Recent filings [All 427 filings](/companies/nktx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-10 | 16:19 ET | [10-Q](/filings/0001787400-26-000017.md) | Quarterly report, period 2026-06-30 | 0001787400-26-000017 | | 2026-08-10 | 16:12 ET | [8-K](/filings/0001193125-26-342402.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-342402 | | 2026-06-11 | 16:59 ET | [8-K](/filings/0001193125-26-267830.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-267830 | | 2026-05-19 | 16:03 ET | [SCHEDULE 13D/A](/filings/0001072613-26-000486.md) | Ownership report, active investor, amended | 0001072613-26-000486 | | 2026-05-12 | 16:09 ET | [10-Q](/filings/0001787400-26-000013.md) | Quarterly report, period 2026-03-31 | 0001787400-26-000013 | | 2026-05-12 | 16:04 ET | [8-K](/filings/0001787400-26-000012.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001787400-26-000012 | | 2026-04-23 | 16:41 ET | [DEF 14A](/filings/0001140361-26-016403.md) | Proxy statement, period 2026-06-10 | 0001140361-26-016403 | | 2026-03-26 | 17:55 ET | [8-K](/filings/0001787400-26-000008.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001787400-26-000008 | | 2026-03-25 | 16:07 ET | [10-K](/filings/0001787400-26-000006.md) | Annual report, period 2025-12-31 | 0001787400-26-000006 | | 2026-03-25 | 16:04 ET | [8-K](/filings/0001787400-26-000005.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001787400-26-000005 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001787400-26-000006.md), filed Mar 25, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1787400 - Tickers: NKTX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.